文献速递肝病

应对代谢功能障碍相关脂肪性肝病(MASLD)与代谢功能障碍相关脂肪性肝炎(MASH)的高企且不断上升的全球负担:从患病率增长到支付方视角

Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.
PubMed 文献 · Aliment Pharmacol Ther · 2025-02-18

本文从支付方视角综述MASLD全球负担,指出其患病率持续上升,带来沉重医疗经济负担,且存在认知不足、无创诊断不精确和预防干预不力等问题。专家圆桌会议强调需加强诊断、治疗和预防措施的战略部署,优先预防代谢失调并及时治疗以降低疾病成本。

要点

  • MASLD全球患病率持续上升,造成显著医疗经济负担并影响患者健康。
  • 认知不足、无创诊断不精确和预防干预不力是MASLD相关问题的核心。
  • 优先预防代谢失调并及时治疗可望降低MASLD进展和疾病成本。

核心结论

  • MASLD全球负担高且不断增长,优先预防代谢失调并及时治疗可形成整体策略以应对MASLD及其进展,并可能降低疾病成本。

研究设计与样本

  • 综述全球MASLD综合负担,基于2023年11月第七届代谢连续统一体圆桌会议专家组的讨论与见解,会议聚焦支付方和社会视角下的负担、患者报告结局和健康经济学。

主要发现

  • 代谢综合征谱涵盖影响肥胖相关胰岛素抵抗、血糖稳态、脂质代谢和促炎免疫反应的一系列功能障碍。
  • 近几十年来包括糖尿病、慢性肝病、心血管代谢疾病和肾脏疾病在内的代谢性疾病全球患病率激增,显著贡献于人群死亡率。
  • MASLD(旧称非酒精性脂肪性肝病)是全球肝病的主要原因,其患病率上升带来重大全球健康挑战,对医疗系统造成沉重负担,影响患者福祉并产生显著经济成本。
  • 认知不足、无创诊断方法不精确和预防干预无效是MASLD相关问题的核心组成部分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity-linked insulin resistance, glucose homeostasis, lipid metabolism and pro-inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well-being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non-invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD-related problem. AIM: The aim of this article was to summarise the global burden of MASLD from the payer's perspective. METHODS: We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient-reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively. CONCLUSION: The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs. TRIAL REGISTRATION: NCT06309992.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Razavi H, Sherman M, et al. Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Aliment Pharmacol Ther. 2025. PMID: 39967239. doi:10.1111/apt.70020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。